Pay attention to the construction strategies of ophthalmic microneedle system

doi:10.3877/cma.j.issn.2095-2007.2022.05.001

Abstract

Abstract:

Ophthalmic microneedles is a novel system drug formulations for eyes, and consists of micron-scale needle arrays. Compared with traditional approaches such as topical and intravitreal routes, microneedles achieve more painless and efficient drug delivery, owing to its ability to overcome the barrier function of ocular tissues. Recently, the research about microneedles constructing new ways of drug delivery has been making progress. However, at present domestic researcher paid little attention to it. The recent progress onthe advantages of microneedles, the system construction strategy, security and existing problems were reviewed in this paper.

Key words: Ocular drug delivery, Microneedles, Minimally-invasive technique, Coated microneedles

Chenxin Geng, Haozhe Yu, Yun Feng. Pay attention to the construction strategies of ophthalmic microneedle system[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(05): 257-261.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2022.05.001

https://zhykyxzz.cma-cmc.com.cn/EN/Y2022/V12/I05/257

References 55

[1]	Yeh S, Khurana RN, Shah M, et al. Efficacy and Safety of Suprachoroidal CLS－TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial[J]. Ophthalmology, 2020, 127(7): 948-955.
[2]	Gerstel MS, Place VA. Drug delivery device: US, US3964482A[P/OL]. 1976－06－22.
[3]	Henry S, McAllister DV, Allen MG, et al. Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery[J]. Journal of Pharmaceutical Sciences, 1998, 87(8): 922-925.
[4]	Jiang J, Gill HS, Ghate D, et al. Coated microneedles for drug delivery to the eye[J]. Investigative Ophthalmology & Visual Science, 2007, 48(9): 4038-4043.
[5]	Huang HS, Schoenwald RD, Lach JL. Corneal penetration behavior of beta－blocking agents III: In vitro－in vivo correlations[J]. J Pharm Sci, 1983, 72(11): 1279-1281.
[6]	Hughes PM, Olejnik O, Chang－Lin JE, et al. Topical and systemic drug delivery to the posterior segments[J]. Adv Drug Deliv Rev, 2005, 57(14): 2010-2032.
[7]	Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug delivery[J]. The AAPS journal, 2010, 12(3): 348-360.
[8]	Jiang J, Moore JS, Edelhauser HF, et al. Intrascleral Drug Delivery to the Eye Using Hollow Microneedles[J]. Pharmaceutical Research, 2009, 26(2): 395-403.
[9]	Mahadevan G, Sheardown H, Selvaganapathy P. PDMS embedded microneedles as a controlled release system for the eye[J]. Journal of Biomaterials Applications, 2012, 28(1): 20-27.
[10]	Patel SR, Lin ASP, Edelhauser HF, et al. Suprachoroidal drug delivery to the back of the eye using hollow microneedles[J]. Pharmaceutical Research, 2011, 28(1): 166-176.
[11]	Schoenwald R. Ocular drug delivery: Pharmacokinetic considerations[J]. Clin Pharmacokinet, 1990, 18(4): 255-269.
[12]	Mikkelson TJ, Chrai SS, Robinson JR. Competitive inhibition of drug－protein interaction in eye fluids and tissues[J]. Journal of Pharmaceutical Sciences, 2010, 62(12): 1942-1945.
[13]	Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery[J]. Ther Deliv, 2010, 1(3): 435-456.
[14]	Kansara V, Mitra AK. Evaluation of an Ex Vivo Model Implication for Carrier－Mediated Retinal Drug Delivery[J]. Current Eye Research, 2006, 31(5): 415-426.
[15]	Ranta VP, Mannermaa E, Lummepuro K, et al. Barrier analysis of periocular drug delivery to the posterior segment[J]. Journal of Controlled Release, 2010, 148(1): 42-48.
[16]	Einmahl S, Savoldelli M, D'Hermies F, et al. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye[J]. Investigative Ophthalmology and Visual Science, 2002, 43(5): 1533-1539.
[17]	Rai UDJP, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye[J]. Drug Discovery Today, 2015, 20(4): 491-495.
[18]	Ínaltekin A, Bozkurt E, Kvrak Y. Factors Associated with Pain Level in Patients Receiving Intravitreal Injection[J]. J Curr Ophthalmol, 2021, 33(3): 323-329.
[19]	Gill HS, Denson DD, Burris BA, et al. Effect of microneedle design on pain in human volunteers[J]. Clin J Pain, 2008, 24(7): 585-594.
[20]	Bal SM, Caussin J, Pavel S, et al. In vivo assessment of safety of microneedle arrays in human skin[J]. European Journal of Pharmaceutical Sciences, 2008, 35(3): 193-202.
[21]	Aoyagi S, Izumi H, Isono Y, et al. Laser fabrication of high aspect ratio thin holes on biodegradable polymer and its application to a microneedle[J]. Sensors and Actuators a－Physical, 2007, 139(1-2): 293-302.
[22]	Parker ER, Rao MP, Turner KL, et al. Bulk micromachined titanium microneedles[J]. Journal of Microelectromechanical Systems, 2007, 16(2): 289-295.
[23]	Kim YC, Park J－H, Prausnitz MR. Microneedles for drug and vaccine delivery[J]. Advanced Drug Delivery Reviews, 2012, 64(14): 1547-1568.
[24]	Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery[J]. Journal of Controlled Release, 2007, 117(2): 227-237.
[25]	Kim SW, Ha BJ, Kim EK, et al. The Effect of Topical Bevacizumab on Corneal Neovascularization[J]. Ophthalmology, 2008, 115(6): e33-e38.
[26]	Kim YC, Grossniklaus HE, Edelhauser HF, et al. Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization[J]. Invest Ophthalmol Vis Sci, 2014, 55(11): 7376-7386.
[27]	Song HB, Lee KJ, Seo IH, et al. Impact insertion of transfer－molded microneedle for localized and minimally invasive ocular drug delivery[J]. J Control Release, 2015, 209: 272-279.
[28]	Khandan O, Kahook MY, Rao MP. Fenestrated microneedles for ocular drug delivery[J]. Sensors and Actuators B: Chemical, 2016, 223: 15-23.
[29]	Patel SR, Berezovsky DE, McCarey BE, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye[J]. Invest Ophthalmol Vis Sci, 2012, 53(8): 4433-4441.
[30]	Chiang B, Kim YC, Edelhauser HF, et al. Circumferential flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries[J]. Exp Eye Res, 2016, 145: 424-431.
[31]	Jung JH, Chiang B, Grossniklaus HE, et al. Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle[J]. J Control Release, 2018, 277: 14-22.
[32]	Gilger BC, Abarca EM, Salmon JH, et al. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles[J]. Invest Ophthalmol Vis Sci, 2013, 54(4): 2483-2492.
[33]	Chiang B, Kim YC, Doty AC, et al. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine－loaded poly(lactic acid) microspheres for the treatment of glaucoma[J]. Journal of Controlled Release, 2016, 228: 48-57.
[34]	Chae JJ, Jung JH, Zhu W, et al. Drug－Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel[J]. Adv Sci (Weinh), 2020, 8(2): 2001908-2001908.
[35]	Olsen TW, Feng X, Wabner K, et al. Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model[J]. Invest Ophthalmol Vis Sci, 2011, 52(7): 4749-4756.
[36]	Thakur RRS, Tekko IA, Al－Shammari F, et al. Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery[J]. Drug Deliv Transl Re, 2016, 6(6): 800-815.
[37]	Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery[J]. Journal of Controlled Release, 2005, 104(1): 51-66.
[38]	Wang QL, Zhu DD, Chen Y, et al. A fabrication method of microneedle molds with controlled microstructures[J]. Mat Sci Eng C－Mater, 2016, 65: 135-142.
[39]	Mogusala V, Venisetty RK. Fabrication of Microneedle Molds and Polymer Based Biodegradable Microneedle Patches: A Novel Method[J]. American Journal of Drug Delivery and Therapeutics, 2015, 2: 1-12.
[40]	Than A, Liu C, Chang H, et al. Self－implantable double－layered micro－drug－reservoirs for efficient and controlled ocular drug delivery[J]. Nature Communications, 2018, 9(1): 4433.
[41]	Wu Y, Vora LK, Wang Y, et al. Long－acting nanoparticle－loaded bilayer microneedles for protein delivery to the posterior segment of the eye[J]. Eur J Pharm Biopharm, 2021, 165: 306-318.
[42]	Palakurthi NK, Correa ZM, Augsburger JJ, et al. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study[J]. J Ocul Pharmacol Ther, 2011, 27(2): 151-156.
[43]	Roy G, Galigama RD, Thorat VS, et al. Amphotericin B containing microneedle ocular patch for effective treatment of fungal keratitis[J]. Int J Pharm, 2019, 572: 118808.
[44]	Park S, Lee K, Kang H, et al. Single Administration of a Biodegradable, Separable Microneedle Can Substitute for Repeated Application of Eyedrops in the Treatment of Infectious Keratitis[J]. Adv Healthc Mater, 2021, 10(11): e2002287.
[45]	Cui M, Zheng M, Wiraja C, et al. Ocular Delivery of Predatory Bacteria with Cryomicroneedles Against Eye Infection[J]. Adv Sci (Weinh), 2021, 8(21): e2102327.
[46]	Donnelly RF, Singh TR, Garland MJ, et al. Hydrogel－Forming Microneedle Arrays for Enhanced Transdermal Drug Delivery[J]. Adv Funct Mater, 2012, 22(23): 4879-4890.
[47]	Turner JG, White LR, Estrela P, et al. Hydrogel－Forming Microneedles: Current Advancements and Future Trends[J]. Macromol Biosci, 2021, 21(2): e2000307.
[48]	Amer M, Chen RK. Self－Adhesive Microneedles with Interlocking Features for Sustained Ocular Drug Delivery[J]. Macromolecular Bioscience, 2020, 20(6): 2000089.
[49]	Fang G, Yang X, Wang Q, et al. Hydrogels－based ophthalmic drug delivery systems for treatment of ocular diseases[J]. Mater Sci Eng C Mater Biol Appl, 2021, 127: 112212.
[50]	Kim YC, Edelhauser HF, Prausnitz MR. Targeted Delivery of Antiglaucoma Drugs to the Supraciliary Space Using Microneedles[J]. Investigative Ophthalmology & Visual Science, 2014, 55(11): 7387-7397.
[51]	Chehab HE, Le Corre A, Agard E, et al. Effect of Topical Pressure－Lowering Medication on Prevention of Intraocular Pressure Spikes after Intravitreal Injection[J]. European Journal of Ophthalmology, 2012, 23(3): 277-283.
[52]	Matthews A, Hutnik C, Hill K, et al. Indentation and needle insertion properties of the human eye[J]. Eye (Lond), 2014, 28(7): 880-887.
[53]	Chung SH, Mollhoff IN, Mishra A, et al. Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes[J]. Hum Gene Ther, 2021, 32(13-14): 682-693.
[54]	Matthaei M, Meng H, Bhutto I, et al. Systematic assessment of microneedle injection into the mouse cornea[J]. Eur J Med Res, 2012, 17(1): 19.
[55]	Goldstein DA. Achieving drug delivery via the suprachoroidal space: Use of the suprachoroidal space for drug delivery may achieve sustained delivery of therapeutics close to the source of retinal or choroidal pathology[J]. Retina Today, 2014, 14: 82-83.

Please choose a citation manager

Content to export